Contact
searchSearch
HMP Global
Login

Non-Hodgkin Lymphomas

Non-Hodgkin Lymphoma
Specialty Channel
FDA Approval
FDA Approves Rituximab Biosimilar for the Treatment of B-Cell Malignancies and Autoimmune Diseases
08/04/2026
Stephanie Holland
The FDA has approved a rituximab biosimilar referencing Rituxan for multiple hematologic malignancies and autoimmune diseases. Approval was supported by a comprehensive biosimilar development program demonstrating high similarity and no...
The FDA has approved a rituximab biosimilar referencing Rituxan for multiple hematologic malignancies and autoimmune diseases. Approval was supported by a comprehensive biosimilar development program demonstrating high similarity and no...
The FDA has approved a rituximab...
08/04/2026
Oncology
News
Ten-Year Follow-Up Supports Curative Potential of Tisagenlecleucel in Patients With B-Cell Non-Hodgkin Lymphomas
06/25/2026
Stephanie Holland
The longest reported follow-up of CD19-directed CAR T-cell therapy demonstrated that a single infusion of tisagenlecleucel produced durable long-term remissions in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, with no...
The longest reported follow-up of CD19-directed CAR T-cell therapy demonstrated that a single infusion of tisagenlecleucel produced durable long-term remissions in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, with no...
The longest reported follow-up...
06/25/2026
Oncology
News
In Vivo CAR T-Cell Therapy Shows Encouraging Early Activity in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
06/16/2026
Emily Estrada
Results from an ongoing phase 1 trial demonstrated that LB2501 shows encouraging activity and promising safety in patients with relapsed or refractory non-Hodgkin lymphomas.
Results from an ongoing phase 1 trial demonstrated that LB2501 shows encouraging activity and promising safety in patients with relapsed or refractory non-Hodgkin lymphomas.
Results from an ongoing phase 1...
06/16/2026
Oncology
News
BAFF-R–Targeted CAR T Therapy Shows Durable Complete Responses in Relapsed B-Cell Lymphoma
06/11/2026
Emily Estrada
Results from a phase 1 study demonstrated that PMB-CT01 elicited durable complete responses with a favorable safety profile in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Results from a phase 1 study demonstrated that PMB-CT01 elicited durable complete responses with a favorable safety profile in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Results from a phase 1 study...
06/11/2026
Oncology
News
Lenalidomide Plus Rituximab Maintains Survival Benefit in R/R Indolent Non-Hodgkin Lymphomas
05/21/2026
Stephanie Holland
Long-term follow-up results from the phase 3 AUGMENT trial show lenalidomide plus rituximab sustained survival benefit in R/R indolent non-Hodgkin lymphomas.
Long-term follow-up results from the phase 3 AUGMENT trial show lenalidomide plus rituximab sustained survival benefit in R/R indolent non-Hodgkin lymphomas.
Long-term follow-up results from...
05/21/2026
Oncology
FDA Approval
FDA Approves Nivolumab Plus Doxorubicin, Vinblastine, and Dacarbazine for Advanced Classical Hodgkin Lymphoma
03/20/2026
Emily Estrada
The FDA approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for adults and adolescents with previously untreated stage III or IV classical Hodgkin lymphoma based on the phase 3 SWOG 1826 trial, which demonstrated significantly...
The FDA approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for adults and adolescents with previously untreated stage III or IV classical Hodgkin lymphoma based on the phase 3 SWOG 1826 trial, which demonstrated significantly...
The FDA approved nivolumab plus...
03/20/2026
Oncology
News
Safety Outcomes of Bendamustine Treatment Among Patients With Indolent Non-Hodgkin Lymphoma in Real-World Setting
03/22/2024
Jordan Kadish
According to a real-world trial and analysis, the safety outcomes of bendamustine treatment among patients with indolent non-Hodgkin lymphoma in routine practice were comparable to trial population outcomes.
According to a real-world trial and analysis, the safety outcomes of bendamustine treatment among patients with indolent non-Hodgkin lymphoma in routine practice were comparable to trial population outcomes.
According to a real-world trial...
03/22/2024
Oncology

News

FDA Approval
FDA Approves Rituximab Biosimilar for the Treatment of B-Cell Malignancies and Autoimmune Diseases
08/04/2026
Stephanie Holland
The FDA has approved a rituximab biosimilar referencing Rituxan for multiple hematologic malignancies and autoimmune diseases. Approval was supported by a comprehensive biosimilar development program demonstrating high similarity and no...
The FDA has approved a rituximab biosimilar referencing Rituxan for multiple hematologic malignancies and autoimmune diseases. Approval was supported by a comprehensive biosimilar development program demonstrating high similarity and no...
The FDA has approved a rituximab...
08/04/2026
Oncology
News
Ten-Year Follow-Up Supports Curative Potential of Tisagenlecleucel in Patients With B-Cell Non-Hodgkin Lymphomas
06/25/2026
Stephanie Holland
The longest reported follow-up of CD19-directed CAR T-cell therapy demonstrated that a single infusion of tisagenlecleucel produced durable long-term remissions in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, with no...
The longest reported follow-up of CD19-directed CAR T-cell therapy demonstrated that a single infusion of tisagenlecleucel produced durable long-term remissions in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, with no...
The longest reported follow-up...
06/25/2026
Oncology
News
In Vivo CAR T-Cell Therapy Shows Encouraging Early Activity in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
06/16/2026
Emily Estrada
Results from an ongoing phase 1 trial demonstrated that LB2501 shows encouraging activity and promising safety in patients with relapsed or refractory non-Hodgkin lymphomas.
Results from an ongoing phase 1 trial demonstrated that LB2501 shows encouraging activity and promising safety in patients with relapsed or refractory non-Hodgkin lymphomas.
Results from an ongoing phase 1...
06/16/2026
Oncology
News
BAFF-R–Targeted CAR T Therapy Shows Durable Complete Responses in Relapsed B-Cell Lymphoma
06/11/2026
Emily Estrada
Results from a phase 1 study demonstrated that PMB-CT01 elicited durable complete responses with a favorable safety profile in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Results from a phase 1 study demonstrated that PMB-CT01 elicited durable complete responses with a favorable safety profile in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Results from a phase 1 study...
06/11/2026
Oncology
News
Lenalidomide Plus Rituximab Maintains Survival Benefit in R/R Indolent Non-Hodgkin Lymphomas
05/21/2026
Stephanie Holland
Long-term follow-up results from the phase 3 AUGMENT trial show lenalidomide plus rituximab sustained survival benefit in R/R indolent non-Hodgkin lymphomas.
Long-term follow-up results from the phase 3 AUGMENT trial show lenalidomide plus rituximab sustained survival benefit in R/R indolent non-Hodgkin lymphomas.
Long-term follow-up results from...
05/21/2026
Oncology
FDA Approval
FDA Approves Nivolumab Plus Doxorubicin, Vinblastine, and Dacarbazine for Advanced Classical Hodgkin Lymphoma
03/20/2026
Emily Estrada
The FDA approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for adults and adolescents with previously untreated stage III or IV classical Hodgkin lymphoma based on the phase 3 SWOG 1826 trial, which demonstrated significantly...
The FDA approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for adults and adolescents with previously untreated stage III or IV classical Hodgkin lymphoma based on the phase 3 SWOG 1826 trial, which demonstrated significantly...
The FDA approved nivolumab plus...
03/20/2026
Oncology
News
Safety Outcomes of Bendamustine Treatment Among Patients With Indolent Non-Hodgkin Lymphoma in Real-World Setting
03/22/2024
Jordan Kadish
According to a real-world trial and analysis, the safety outcomes of bendamustine treatment among patients with indolent non-Hodgkin lymphoma in routine practice were comparable to trial population outcomes.
According to a real-world trial and analysis, the safety outcomes of bendamustine treatment among patients with indolent non-Hodgkin lymphoma in routine practice were comparable to trial population outcomes.
According to a real-world trial...
03/22/2024
Oncology

Interactive Features

Recent News

FDA Approval
FDA Approves Rituximab Biosimilar for the Treatment of B-Cell Malignancies and Autoimmune Diseases
08/04/2026
Stephanie Holland
The FDA has approved a rituximab biosimilar referencing Rituxan for multiple hematologic malignancies and autoimmune diseases. Approval was supported by a comprehensive biosimilar development program demonstrating high similarity and no...
The FDA has approved a rituximab biosimilar referencing Rituxan for multiple hematologic malignancies and autoimmune diseases. Approval was supported by a comprehensive biosimilar development program demonstrating high similarity and no...
The FDA has approved a rituximab...
08/04/2026
Oncology
News
Ten-Year Follow-Up Supports Curative Potential of Tisagenlecleucel in Patients With B-Cell Non-Hodgkin Lymphomas
06/25/2026
Stephanie Holland
The longest reported follow-up of CD19-directed CAR T-cell therapy demonstrated that a single infusion of tisagenlecleucel produced durable long-term remissions in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, with no...
The longest reported follow-up of CD19-directed CAR T-cell therapy demonstrated that a single infusion of tisagenlecleucel produced durable long-term remissions in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, with no...
The longest reported follow-up...
06/25/2026
Oncology
News
In Vivo CAR T-Cell Therapy Shows Encouraging Early Activity in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
06/16/2026
Emily Estrada
Results from an ongoing phase 1 trial demonstrated that LB2501 shows encouraging activity and promising safety in patients with relapsed or refractory non-Hodgkin lymphomas.
Results from an ongoing phase 1 trial demonstrated that LB2501 shows encouraging activity and promising safety in patients with relapsed or refractory non-Hodgkin lymphomas.
Results from an ongoing phase 1...
06/16/2026
Oncology
News
BAFF-R–Targeted CAR T Therapy Shows Durable Complete Responses in Relapsed B-Cell Lymphoma
06/11/2026
Emily Estrada
Results from a phase 1 study demonstrated that PMB-CT01 elicited durable complete responses with a favorable safety profile in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Results from a phase 1 study demonstrated that PMB-CT01 elicited durable complete responses with a favorable safety profile in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Results from a phase 1 study...
06/11/2026
Oncology
News
Lenalidomide Plus Rituximab Maintains Survival Benefit in R/R Indolent Non-Hodgkin Lymphomas
05/21/2026
Stephanie Holland
Long-term follow-up results from the phase 3 AUGMENT trial show lenalidomide plus rituximab sustained survival benefit in R/R indolent non-Hodgkin lymphomas.
Long-term follow-up results from the phase 3 AUGMENT trial show lenalidomide plus rituximab sustained survival benefit in R/R indolent non-Hodgkin lymphomas.
Long-term follow-up results from...
05/21/2026
Oncology
FDA Approval
FDA Approves Nivolumab Plus Doxorubicin, Vinblastine, and Dacarbazine for Advanced Classical Hodgkin Lymphoma
03/20/2026
Emily Estrada
The FDA approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for adults and adolescents with previously untreated stage III or IV classical Hodgkin lymphoma based on the phase 3 SWOG 1826 trial, which demonstrated significantly...
The FDA approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for adults and adolescents with previously untreated stage III or IV classical Hodgkin lymphoma based on the phase 3 SWOG 1826 trial, which demonstrated significantly...
The FDA approved nivolumab plus...
03/20/2026
Oncology
News
Safety Outcomes of Bendamustine Treatment Among Patients With Indolent Non-Hodgkin Lymphoma in Real-World Setting
03/22/2024
Jordan Kadish
According to a real-world trial and analysis, the safety outcomes of bendamustine treatment among patients with indolent non-Hodgkin lymphoma in routine practice were comparable to trial population outcomes.
According to a real-world trial and analysis, the safety outcomes of bendamustine treatment among patients with indolent non-Hodgkin lymphoma in routine practice were comparable to trial population outcomes.
According to a real-world trial...
03/22/2024
Oncology
News
Ociperlimab Plus Tislelizumab Fails to Improve Survival Over Pembrolizumab in PD-L1-High Advanced Non-Small Cell Lung Cancer
08/11/2026
Emily Estrada
Ociperlimab plus tislelizumab failed to improve overall survival compared with pembrolizumab as first-line treatment for patients with stage III/IV non-small cell lung cancer and PD-L1 expression of ≥50%, leading to the phase 3 AdvanTIG-302...
Ociperlimab plus tislelizumab failed to improve overall survival compared with pembrolizumab as first-line treatment for patients with stage III/IV non-small cell lung cancer and PD-L1 expression of ≥50%, leading to the phase 3 AdvanTIG-302...
Ociperlimab plus tislelizumab...
08/11/2026
Oncology
News
IO102-IO103 Plus Nivolumab and Relatlimab Demonstrates Encouraging Activity in Unresectable Melanoma
08/05/2026
Stephanie Holland
A phase 2 trial demonstrated that the investigational cancer vaccine IO102-IO103 combined with nivolumab and relatlimab achieved a 60% objective response rate in previously untreated unresectable melanoma, supporting further evaluation of the...
A phase 2 trial demonstrated that the investigational cancer vaccine IO102-IO103 combined with nivolumab and relatlimab achieved a 60% objective response rate in previously untreated unresectable melanoma, supporting further evaluation of the...
A phase 2 trial demonstrated...
08/05/2026
Oncology
News
HBI-8000 Plus Nivolumab Significantly Improves Progression-Free Survival in Advanced Melanoma
08/05/2026
Stephanie Holland
Topline results from a global phase 3 trial demonstrated that HBI-8000 plus nivolumab significantly improved progression-free survival compared with nivolumab alone in patients with advanced melanoma, supporting the combination as a potential...
Topline results from a global phase 3 trial demonstrated that HBI-8000 plus nivolumab significantly improved progression-free survival compared with nivolumab alone in patients with advanced melanoma, supporting the combination as a potential...
Topline results from a global...
08/05/2026
Oncology
FDA Approval
FDA Approves Rituximab Biosimilar for the Treatment of B-Cell Malignancies and Autoimmune Diseases
08/04/2026
Stephanie Holland
The FDA has approved a rituximab biosimilar referencing Rituxan for multiple hematologic malignancies and autoimmune diseases. Approval was supported by a comprehensive biosimilar development program demonstrating high similarity and no...
The FDA has approved a rituximab biosimilar referencing Rituxan for multiple hematologic malignancies and autoimmune diseases. Approval was supported by a comprehensive biosimilar development program demonstrating high similarity and no...
The FDA has approved a rituximab...
08/04/2026
Oncology
FDA Alerts
FDA Advisory Committee Backs RP1 Plus Nivolumab for Advanced Melanoma in 10-3 Vote
07/31/2026
Stephanie Holland
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 that efficacy findings from the phase 2 IGNYTE trial of RP1 (vusolimogene oderparepvec) plus nivolumab are clinically meaningful, supporting the investigational...
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 that efficacy findings from the phase 2 IGNYTE trial of RP1 (vusolimogene oderparepvec) plus nivolumab are clinically meaningful, supporting the investigational...
The FDA's Cellular, Tissue, and...
07/31/2026
Oncology
FDA Alerts
Subcutaneous Amivantamab Receives FDA Priority Review for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
07/30/2026
Emily Estrada
The FDA granted Priority Review to subcutaneous amivantamab and hyaluronidase for previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma, supported by results from the phase 1b/2 OrigAMI-4 trial.
The FDA granted Priority Review to subcutaneous amivantamab and hyaluronidase for previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma, supported by results from the phase 1b/2 OrigAMI-4 trial.
The FDA granted Priority Review...
07/30/2026
Oncology
News
Regorafenib Produces High Response and Durable Disease Control in KIT-Mutant Advanced Melanoma
07/29/2026
Stephanie Holland
The phase 2 RegoMel trial demonstrated that continuous daily regorafenib produced clinically meaningful antitumor activity in heavily pretreated advanced melanoma, with particularly high response rates in KIT-mutant disease and encouraging...
The phase 2 RegoMel trial demonstrated that continuous daily regorafenib produced clinically meaningful antitumor activity in heavily pretreated advanced melanoma, with particularly high response rates in KIT-mutant disease and encouraging...
The phase 2 RegoMel trial...
07/29/2026
Oncology
News
Ceralasertib Plus Durvalumab Demonstrates Limited Activity in PD-L1-Resistant Advanced Melanoma
07/29/2026
Stephanie Holland
The phase 2 MONETTE trial found that ceralasertib, administered alone or in combination with durvalumab, produced low response rates in patients with anti–PD-L1-resistant advanced melanoma, while exploratory analyses identified higher...
The phase 2 MONETTE trial found that ceralasertib, administered alone or in combination with durvalumab, produced low response rates in patients with anti–PD-L1-resistant advanced melanoma, while exploratory analyses identified higher...
The phase 2 MONETTE trial found...
07/29/2026
Oncology
News
Real-World Study Demonstrates Rapid Pain Relief, Durable Disease Control, and Manageable Safety With Nirogacestat in Young Adults With Desmoid Tumors
07/28/2026
Emily Estrada
A real-world study found that nirogacestat provided rapid pain relief, durable disease control, and a manageable safety profile in young adults with desmoid tumors, supporting its use in routine clinical practice while emphasizing the...
A real-world study found that nirogacestat provided rapid pain relief, durable disease control, and a manageable safety profile in young adults with desmoid tumors, supporting its use in routine clinical practice while emphasizing the...
A real-world study found that...
07/28/2026
Oncology
News
Real-World Study Highlights Evolving Treatment Patterns and Persistent Diagnostic Challenges in Patients With Desmoid Tumors
07/28/2026
Emily Estrada
Real-world findings demonstrated declining use of surgery and increasing adoption of systemic therapies for desmoid tumors, while highlighting substantial symptom burden, frequent treatment changes, and increased healthcare resource...
Real-world findings demonstrated declining use of surgery and increasing adoption of systemic therapies for desmoid tumors, while highlighting substantial symptom burden, frequent treatment changes, and increased healthcare resource...
Real-world findings demonstrated...
07/28/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use